factor VIII

Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms, Wikipedia.

Related to factor VIII: Factor VIII deficiency

factor VIII

[′fak·tər ′āt]

(biochemistry)

Mentioned in ?

References in periodicals archive ?

Iran announced in February that a pharmaceutical company based in the northeastern city of Mashhad had managed to produce Factor VIII, becoming one of the few in the world to attain the knowledge needed for the production of the drug.

Vice-President Condemns Foreign Pharmaceutical Companies' Dumping against Iranian Rivals

STASEY study is a phase IIIb clinical trial to evaluate the safety and tolerability of Hemlibra in people with hemophilia A with factor VIII inhibitors.

Chugai Pharmaceutical Co., Ltd. - Further Clinical Data including Long-Term Follow-up for Chugai's Hemlibra Presented at ISTH -- 9/7/2019

Updated data from the pooled HAVEN studies (HAVEN 1, HAVEN 2, HAVEN 3 and HAVEN 4; n=400), in people with hemophilia A of all ages with and without factor VIII inhibitors, showed that a high proportion of patients experienced zero treated bleeds on Hemlibra, and that this was maintained over a median of 83 weeks.

Genentech Presents a Broad Range of Data for Hemlibra Demonstrating Continued Benefits for People with Hemophilia A at the ISTH 2019 Congress

HAVEN 1 has formed the basis of Hemlibras approval in people with haemophilia A with factor VIII inhibitors in over 70 countries worldwide to date.

Switzerland : Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress

"These data confirm that valoctocogene roxaparvovec has the potential to profoundly impact the lives of people with severe hemophilia A through a sustained reduction in bleeds and factor VIII usage," said Hank Fuchs, M.D., President, Global Research and Development at BioMarin.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) - BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A -- 28/5/2019

Conclusion: In conclusion, though development of factor VIII inhibitors has not yet become major issue in our population and only 4.5% haemophiliaA patients developed inhibitors in present study.

FREQUENCY AND LEVELS OF FACTOR EIGHT INHIBITORS IN KNOWN HAEMOPHILIACS

In the intraindividual comparison involving 48 participants in group D, the annualized bleeding rate was 68 percent lower with emicizumab prophylaxis compared with the rate with previous factor VIII prophylaxis.

Emicizumab Prophylaxis Cuts Bleeding in Hemophilia A; Lower bleeding rate with administration once weekly, every two weeks versus no prophylaxis

The global hemophilia treatment market segmentation is based on drug type (antifibrinolytic agents, desmopressin, plasma derived coagulation factor concentrates - factor VIII, factor IX, combination, recombinant coagulation factor concentrates - factor VIII, factor IX, combination), indication type (acquired hemophilia, hemophilia a, hemophilia b, hemophilia c), and distribution channel (e-commerce, hospital pharmacies, retail pharmacies).

Hemophilia Treatment Market by Drugs, Distribution Channels, Trends and Forecast to 2021, Upcoming Research by iHealthcareAnalyst, Inc.

In one of our earlier studies we had reported 45 documented cases with 36 (81%) factor VIII deficiency, 8 (17%) factor IX deficiency and one factor X deficiency case.

Clinical profile of haemophilia patients of upper Assam--a hospital-based study

(2.) Mazurier C, Dieval J, JorieuxS, Delobel J, Goudemand M.A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF.

Prolonged Bleeding in a 34-Year-Old Man following Oral Surgery

The funds are earmarked to the HemAcure consortium with the goal to bring treatment of hemophilia A, also called factor VIII deficiency--the most common form of hemophilia A--into the clinic for human trials.

Implantable cell-based device could offer treatment for hemophilia

The Bethesda test confirmed an elevated level of factor VIII inhibitor at 6.16 IU/mL (normal 0.0 IU/mL) and a low level of factor VIII at 0.02 IU/mL (normal 0.5-1.50 IU/mL), confirming a diagnosis of acquired hemophilia A.